P2.06-021 Efficacy and Safety of ASP8273 versus Erlotinib or Gefitinib as First-Line Treatment in Subjects with EGFRMut+ NSCLC: Topic: Phase IIIRonan J. Kelly,Leora Horn,James Chih-Hsin Yang,Dae Ho Lee,Bhardwaj Desai, Tanya Fleege,Fei Jie,Srinivasu Poondru,Anne Keating, Debbie Whitcomb,Tosei Murase,Koichi Uegaki, Kouji Aoyama,Kazuhiko NakagawaJournal of Thoracic Oncology（2017）引用 1|浏览7暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
